

Fax: +49 941 944-4233 or  
Online registration:  
www.congress-registration.ukr.de

### GvH/GvL 2022 – 15th International Symposium

#### Venue and Date

**March 9 to 11, 2022**  
Online (GHV-2203)

Your registration is binding. In case of a cancellation the cancellation statement must be in writing.

Title .....

First name .....

Last name .....

Hospital .....

Department .....

Address .....

Phone .....

Mail .....

.....  
Date Signature

#### Sponsors

AbbVie Deutschland GmbH & Co. KG	1.000 €
Alexion Pharma Germany GmbH	1.000 €
Amgen GmbH	2.000 €
Astellas Pharma GmbH	1.500 €
AstraZeneca GmbH	1.500 €
Bristol-Myers Squibb GmbH & Co KGaA	2.000 €
Hexal AG	1.000 €
Janssen-Cilag GmbH	1.500 €
Medac GmbH	3.500 €
Miltenyi Biotec B.V. & Co. KG	1.000 €
MSD Sharp & Dohme GmbH	1.000 €
Neovii Biotech GmbH	5.000 €
Novartis Pharma GmbH	500 €
Pfizer Pharma GmbH	2.500 €
Roche Pharma GmbH	1.000 €
Stemline Therapeutics Switzerland GmbH	1.000 €
Takeda Pharma Vertrieb GmbH & Co. KG	3.000 €

We also thank Neovii Biotech GmbH for sponsoring the Hans-Jochem-Kolb-Award with 5.000 €.

#### Venue

Online

#### Organisation

*Britta Haseneder*  
University Hospital Regensburg  
Phone: +49 941 944-4230  
Fax: +49 941 944-4233  
kongresse@ukr.de

#### Information

*Susanna Piltauer*  
Department of Internal Medicine III  
University Hospital Regensburg  
Phone: +49 941 944-5542  
Fax: +49 941 944-5543  
susanna.piltauer@ukr.de

#### Participation Fee

Online fee 60 €

#### Condition for Participation & Cancellation


After your successful registration you will receive an invoice concerning your participation fee during the next days by email. Once registered your registration is binding. All payments must be made prior to the conference. Participation fees are due upon receipt of invoice without deduction. Please transfer the invoice amount before the event date. In case of a cancellation the cancellation statement must be in writing. The following processing fees apply: 8-3 working days before the event 50% of participation fee. In case of too late cancellation or absence without written cancellation the entire fee will be charged. A substitute participant may be submitted at any time.

GRAFT VERSUS HOST

**G>H**

**G>L**

GRAFT VERSUS LEUKEMIA



Graft versus Host Competence Center  
Department of Internal Medicine III

**GvH/GvL 2022**  
15th International Symposium

Digital Symposium

March 9 to 11, 2022

## Dear colleagues,

It is our great honour and pleasure to welcome you to the 15th GvH/GvL meeting in Regensburg. Since the first GvH/GvL conferences the idea of a focused and interactive meeting allowing extensive exchange and discussion among experts and young scientists and stimulating on site development of concepts and ideas still seems to meet the needs and the interest of many colleagues involved in the field of allogeneic stem cell transplantation and clinical immunobiology.

Nowadays, we are confronted with exciting new developments like the integration of CAR-T cell therapy, new treatment options in GvHD, GvHD modulation by post-transplant cyclophosphamide or the concept of tissue tolerance.

We are more than grateful, so many distinguished experts from all over the world have again accepted our invitation to contribute as speakers, chairs and discussants. Although this year's meeting is due to the unresolved pandemic situation a hybrid meeting, combining online and onsite presentations, we still hope to be able to realize a creative and stimulating exchange.

We hope you enjoy our meeting.

### Local Scientific Committee

*Ernst Holler MD*

*Daniel Wolff MD*

*Hendrik Poeck MD*

*Wolfgang Herr MD*

*Matthias Edinger MD*

## Wednesday, March 9th, 2022

1.00 pm **Welcome**

### Session I: Pathophysiology – new aspects

Chair: M. Edinger

1.15 pm **CD162 pos macrophages and GvHD**

A. Beilhack, Würzburg

1.40 pm **Sting/IFN signaling and microbiota**

H. Poeck, Regensburg

2.05 pm **Role of neutrophils**

R. Zeiser, Freiburg

2.30 pm **Tissue tolerance**

P. Reddy, Ann Arbor

2.55 pm **IL22 and intestinal stem cells**

A.M. Hanash, New York

3.20 pm **Break**

### Session II: Biomarkers and Pathophysiology II

Chair: A. Beilhack

3.45 pm **Update on MAGIC**

J. Levine, New York

4.10 pm **Tissue T regs**

M. Feuerer, Regensburg

4.35 pm **T Reg repertoire**

C. Koenecke, Hannover

5.00 pm **Interplay between endothelial damage, atherosclerosis and GvHD**

A. Zerneck, Würzburg

5.25 pm **Microbiota and bile acids in murine and human allogeneic SCT**

M. v. d. Brink, New York

5.50 pm **HJ Kolb Award and lecture 2022**

6.45 pm **Evening Discussion**

## Thursday, March 10th, 2022

### Session III: Immune cells and immunoreconstitution

Chair: P. Hoffmann

9.00 am **CD4 reconstitution and outcome**

C. Lindemans, Utrecht

9.25 am **Mechanisms regulating immune reconstitution**

E. Velardi, Rome

9.50 am **Tumor specific T cells in myeloma and HD**

L. Hansmann, Berlin

10:15 am **The role of early CD4<sup>+</sup>T cell add back following allogeneic hematopoietic cell transplantation**

R. Chakraverty, London

10.40 am **Break**

### Session IV: IgA

Chair: A. Gessner

11.00 am **Intestinal IgA, microbiota and immunoregulation**

O. Pabst, Aachen

11.25 am **Chronic GvHD is associated with early expansions of IgA and IgG plasmablasts**

T. Winkler, Erlangen

11.50 am **Intestinal IgA pos plasma cells and GvH/GvL**

E. Holler, Regensburg

12.15 pm **Break**

### Session V: New Treatment Options in acute and chronic GvHD

Chairs: H. Poeck, D. Wolff

1.30 pm **FMT and beyond**

F. Malard, Paris

1.55 pm **T regs in chronic GvHD**

M Edinger, Regensburg

2.20 pm **Wnt signaling in cGvHD**

J. Distler, Erlangen

2.55 pm **RIPK1 inhibition and acute GvHD**

J.L.M. Ferrara, New York

3.20 pm **Drug targetable biomarkers of chronic GvHD**

S. Paczesny, Indianapolis

3.35 pm **Break**

### Keynote lecture

Chairs: S. Thomas, H.J. Kolb

4.00 pm **The role of CAR T cells in the setting of allogeneic SCT**

M. v. d. Brink, New York

4.40 pm **Break**

### Session VI: GvL I

A. Mackensen

5.00 pm **Novel hemibodies for personalized GvL therapy**

G. Stuhler

5.25 pm **DP specific strategies**

K. Fleischhauer, Essen

5.50 pm **Regulation of class II to prevent relapse**

H. Reimann, Erlangen

## Friday, March 11th, 2022

### Session VII: GvL II

Chair: H Einsele

9.00 am **Immune signature drives leukemia escape after aHSCT**

L. Vago, Milano

9.25 am **Harnessing immune exhaustion for adoptive T cell therapy of acute myeloid leukemia**

B. Cianciotti, Milano

9.50 am **mutNPM1 – specific TCR in AML**

M. Griffioen, Leiden

10.15 am **T cell metabolism and immune escape**

D. Mouggiakakos

10.40 am **Coffee Break**

### Session VIII: GvL III

Chairs: P. Beckhove, W. Herr

11.00 am **Genome edited allo-CART**

G. Lucchini, London

11.25 am **Novel targets for CAR T cells in myeloma and AML**

M. Hudecek, Würzburg

11.50 am **CART and memory T stem cells**

L. Gattinoni, Regensburg

12.15 pm **CAR T cell resistance**

L. Rasche, Würzburg

12.40 pm **Closure and farewell**